Synairgen (LON:SNG) Shares Cross Below 200-Day Moving Average of $14.31
Synairgen (LON:SNG) Shares Cross Below 200-Day Moving Average of $14.31
Synairgen plc (LON:SNG – Get Rating) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 14.31 ($0.18) and traded as low as GBX 9.50 ($0.12). Synairgen shares last traded at GBX 9.50 ($0.12), with a volume of 377,264 shares trading hands.
Synairgen plc(伦敦股票代码：SNG-GET)在周五的交易中跌破200日移动均线。该股的200日移动均线为14.31英镑(合0.18美元)，交易价格低至9.50英镑(合0.12美元)。Synairgen的股票最新报9.50英镑(合0.12美元)，成交量为377,264股。
Synairgen Stock Performance
Synairgen股票表现
The company has a debt-to-equity ratio of 0.09, a current ratio of 6.35 and a quick ratio of 6.35. The stock has a 50 day simple moving average of GBX 10.58 and a two-hundred day simple moving average of GBX 14.31. The company has a market cap of £19.13 million, a PE ratio of -55.88 and a beta of -2.29.
该公司的债务权益比为0.09，流动比率为6.35，速动比率为6.35。该股的50日简单移动均线切入位为10.58英镑，200日简单移动均线切入位为14.31英镑。该公司市值为1913万GB，市盈率为-55.88，贝塔系数为-2.29。
Synairgen Company Profile
Synairgen公司简介
(Get Rating)
(获取评级)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Synairgen plc发现和开发治疗呼吸系统疾病的药物。该公司开发的产品有：治疗新冠肺炎的乙型吸入型干扰素SG001；治疗感冒和流感引起的哮喘的乙型干扰素吸入剂；治疗或预防慢性阻塞性肺病的乙型干扰素第二阶段临床试验；以及治疗特发性肺纤维化的LXL2抑制剂。
Featured Stories
专题报道
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
- ExxonMobil Gushes To New Highs
- 如何投资今年最受欢迎的食品杂货股
- 阵列技术将太阳耀斑带到2023年收益预测
- 利率上升前最适合投资的银行股
- 如何投资农田：7个简单的方法
- 埃克森美孚股价创新高
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
接受Synairgen Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Synairgen和相关公司的最新新闻和分析师评级的每日简明摘要。